Contrasting Mateon Therapeutics (MATN) & SIGA Technologies (SIGA)

Mateon Therapeutics (OTCMKTS: MATN) and SIGA Technologies (OTCMKTS:SIGA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Profitability

This table compares Mateon Therapeutics and SIGA Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mateon Therapeutics N/A -210.82% -175.67%
SIGA Technologies -201.85% N/A -23.22%

Volatility and Risk

Mateon Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, SIGA Technologies has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.

Institutional & Insider Ownership

6.7% of SIGA Technologies shares are owned by institutional investors. 4.5% of Mateon Therapeutics shares are owned by insiders. Comparatively, 4.7% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Mateon Therapeutics and SIGA Technologies’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mateon Therapeutics N/A N/A -$13.65 million ($0.56) -0.39
SIGA Technologies $14.99 million 25.43 -$39.69 million ($0.53) -9.11

Mateon Therapeutics has higher earnings, but lower revenue than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mateon Therapeutics and SIGA Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mateon Therapeutics 0 1 3 0 2.75
SIGA Technologies 0 0 0 0 N/A

Mateon Therapeutics currently has a consensus target price of $1.75, indicating a potential upside of 696.54%. Given Mateon Therapeutics’ higher probable upside, analysts plainly believe Mateon Therapeutics is more favorable than SIGA Technologies.

Summary

SIGA Technologies beats Mateon Therapeutics on 6 of the 11 factors compared between the two stocks.

Mateon Therapeutics Company Profile

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

SIGA Technologies Company Profile

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply